IART Integra Lifesciences Holdings Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: IART

Price (delayed)

$70.42

Market cap

$5.95B

P/E Ratio

35.03

Dividend/share

N/A

EPS

$2.01

Enterprise value

$7.3B

Highlights
The stock's price to earnings (P/E) is 55% less than its 5-year quarterly average of 77.7
Integra Lifesciences Holdings's net income has increased by 27% from the previous quarter
IART's quick ratio is down by 38% YoY and by 12% from the previous quarter
The gross profit has declined by 10% year-on-year
Sector: Healthcare
Industry: Medical Devices
Website: https://www.integralife.com/
Peers: SYK TFX XRAY CNMD

Key stats

What are the main financial stats of IART
Market
Shares outstanding
84.55M
Market cap
$5.95B
Enterprise value
$7.3B
Valuations
Price to earnings (P/E)
35.03
Price to book (P/B)
3.88
Price to sales (P/S)
4.32
EV/EBIT
33.76
EV/EBITDA
21.67
EV/Sales
5.3
Earnings
Revenue
$1.38B
EBIT
$216.11M
EBITDA
$336.69M
Free cash flow
$226.68M
Per share
EPS
$2.01
Free cash flow per share
$2.68
Book value per share
$18.13
Revenue per share
$16.3
TBVPS
$18.2
Balance sheet
Total assets
$3.74B
Total liabilities
$2.21B
Debt
$1.75B
Equity
$1.53B
Working capital
$626.77M
Liquidity
Debt to equity
1.14
Current ratio
2.52
Quick ratio
1.53
Net debt/EBITDA
3.98
Margins
EBITDA margin
24.4%
Gross margin
61.3%
Net margin
12.3%
Operating margin
11.2%
Efficiency
Return on assets
4.8%
Return on equity
11.7%
Return on invested capital
8.6%
Return on capital employed
6.5%
Return on sales
15.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IART stock price

How has the Integra Lifesciences Holdings stock price performed over time
Intraday
0.92%
1 week
4.23%
1 month
-1%
1 year
45.5%
YTD
8.47%
QTD
1.93%

Financial performance

How have Integra Lifesciences Holdings's revenue and profit performed over time
Revenue
$1.38B
Gross profit
$844.43M
Operating income
$154.98M
Net income
$170.11M
Gross margin
61.3%
Net margin
12.3%
IART's operating margin has soared by 90% year-on-year
The operating income has surged by 75% year-on-year and by 2.4% since the previous quarter
Integra Lifesciences Holdings's net income has increased by 27% from the previous quarter
The net margin is up by 26% since the previous quarter

Growth

What is Integra Lifesciences Holdings's growth rate over time

Valuation

What is Integra Lifesciences Holdings stock price valuation
P/E
35.03
P/B
3.88
P/S
4.32
EV/EBIT
33.76
EV/EBITDA
21.67
EV/Sales
5.3
The stock's price to earnings (P/E) is 55% less than its 5-year quarterly average of 77.7
IART's EPS is up by 27% since the previous quarter
The P/B is 18% higher than the last 4 quarters average of 3.3 and 8% higher than the 5-year quarterly average of 3.6
The equity has increased by 14% year-on-year
The price to sales (P/S) is 31% more than the 5-year quarterly average of 3.3 and 23% more than the last 4 quarters average of 3.5
The revenue has declined by 9% year-on-year

Efficiency

How efficient is Integra Lifesciences Holdings business performance
IART's return on sales has surged by 124% year-on-year and by 31% since the previous quarter
IART's return on invested capital has surged by 95% year-on-year and by 32% since the previous quarter
IART's ROA is up by 23% QoQ
Integra Lifesciences Holdings's return on equity has increased by 22% QoQ

Dividends

What is IART's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IART.

Financial health

How did Integra Lifesciences Holdings financials performed over time
The company's total assets is 69% higher than its total liabilities
IART's quick ratio is down by 38% YoY and by 12% from the previous quarter
The current ratio has declined by 38% year-on-year and by 18% since the previous quarter
The debt is 14% greater than the equity
The equity has increased by 14% year-on-year
Integra Lifesciences Holdings's debt to equity has decreased by 10% YoY but it has increased by 4.6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.